Shanghai Junshi Biosciences Co., Ltd announced the publication of results from TORCHLIGHT, a randomized, double-blind, placebo-controlled phase 3 study comparing the efficacy and safety of toripalimab versus placebo, in combination with nab-paclitaxel for patients with newly diagnosed metastatic or recurrent locally advanced triple-negative breast cancer in Nature Medicine.
